Biovista

From WikiMD's Wellness Encyclopedia

Biovista is a biotechnology company that specializes in the field of drug repositioning and drug discovery. The company is known for its innovative approach to identifying new uses for existing drugs, which can significantly reduce the time and cost associated with bringing new therapies to market.

History[edit | edit source]

Biovista was founded in 2005 by Aris Persidis and Andreas Persidis. The company is headquartered in Charlottesville, Virginia, and has additional offices in Athens, Greece. Since its inception, Biovista has focused on leveraging its proprietary technology platform to discover new therapeutic applications for existing drugs.

Technology[edit | edit source]

Biovista's core technology is based on a comprehensive bioinformatics platform that integrates data from various sources, including scientific literature, clinical trials, and biomedical databases. This platform allows the company to identify potential drug-disease relationships and predict the efficacy and safety of drug candidates.

Drug Repositioning[edit | edit source]

One of Biovista's primary areas of expertise is drug repositioning, also known as drug repurposing. This process involves finding new therapeutic uses for existing drugs that have already been approved by regulatory agencies such as the Food and Drug Administration (FDA). By repurposing existing drugs, Biovista aims to reduce the risks and costs associated with drug development.

Collaborations and Partnerships[edit | edit source]

Biovista has established numerous collaborations and partnerships with leading pharmaceutical companies, academic institutions, and research organizations. These partnerships enable the company to leverage its technology platform to address unmet medical needs and accelerate the development of new therapies.

Notable Projects[edit | edit source]

Biovista has been involved in several high-profile projects, including collaborations with major pharmaceutical companies to identify new uses for their existing drug portfolios. The company has also worked on projects related to rare diseases, oncology, and neurological disorders.

See Also[edit | edit source]

References[edit | edit source]

External Links[edit | edit source]



Contributors: Prab R. Tumpati, MD